If you believe in innovative AI healthcare stocks, this trio will reset your horizon trajectory

Artificial intelligence in healthcare is one of the clearest ways technology can meet real-world needs, especially as rising energy prices, geopolitical tensions, and persistent inflation continue to pressure costs and productivity. While many sectors face lower activity and higher input prices, AI tools that support better diagnosis, smoother hospital operations, and faster drug discovery have a direct impact on efficiency and outcomes. This screener focuses on companies applying AI to these problems and helps hone in on businesses related to long-term changes in the way care is delivered. Below are three stocks on our list of transformative AI healthcare stocks.

Medtronic (MDT)

overview: Medtronic is a leading medical device company that supplies surgeons and clinicians with products such as cardiac pacemakers and defibrillators, spinal and brain implants, surgical instruments and robotics, and insulin pumps and blood glucose monitors for the treatment of diabetes in the U.S. and international markets.

operation: Medtronic generates most of its revenue from cardiovascular (US$13.5 billion), neuroscience (US$10.2 billion), medical-surgical (US$8.6 billion), and diabetes (US$3 billion), with the United States contributing US$17.8 billion and other countries contributing US$17.6 billion.

Market capitalization: US$110.8 billion

Investors focused on AI in healthcare may find Medtronic interesting. Medtronic’s core cardiac, neurosurgical and surgical device franchises are increasingly intertwined with software, data and robotics, from its AI-powered surgical video platform to its stealth AXiS navigation system and ALERT pilot studies in heart valve care. The company backs this up with extensive research and development, a long-term dividend record with a yield of 3.29%, and profits that analysts expect to grow faster than the recent five-year trend. At the same time, competition in diabetes technology, a history of product recalls, and reliance on external borrowings make risk a constant concern. Knowing the full picture of how these strengths and pressures fit together can reveal real opportunities for you.

Medtronic’s AI-related devices, robotics and software could tell a different story than its headline dividend yield suggests. See how analyst forecasts factor into Medtronic’s analyst forecasts and what’s hiding below.

Insmed (INSM)

overview: Insmed is focused on treating serious rare diseases, with ARIKAYCE, an approved lung infection treatment, and a deep pipeline targeting bronchiectasis, pulmonary hypertension, Duchenne muscular dystrophy, amyotrophic lateral sclerosis, and other difficult-to-treat diseases.

operation: Insmed generates approximately US$606.4 million in revenue from treating patients with rare diseases, including approximately US$453 million from the United States and US$153.5 million from international markets.

Market capitalization: $35.2 billion

Insmed stands out in AI-focused healthcare because, even though its core respiratory and rare disease portfolio is already commercialized, it is tightly tied to upcoming data and approvals that could reshape its business, from brensocatib in bronchiectasis to TPIP in pulmonary hypertension and a potential ARIKAYCE label extension. Analysts have highlighted the potential for revenue and profit growth, which depends on approvals, payer support and successful market access, while the company remains loss-making and dependent on external funding and new equity. For investors willing to take on that risk, the combination of multiple late-stage programs, expanding international reach, and analyst targeting presents a more layered story than a simple high-growth biotech brand would suggest.

Insmed’s late-stage pipeline and focus on rare diseases may be obscuring the broader story of how all these moving parts come together. See how Insmed’s analysis report explains the potential upside along with the risks that could change the outlook.

Striker (SYK)

overview: Stryker is a global medical technology company that provides hospitals and clinicians with surgical equipment, neurotechnical equipment, AI-assisted virtual care and communication platforms, and orthopedic implants for joint replacement and trauma care.

operation: Stryker generates approximately US$9.5 billion from orthopedics and approximately US$15.6 billion from MedSurg and Neurotechnology, with most of its revenue coming from the United States, with additional contributions from Europe, the Middle East, Africa, Asia Pacific, and other international markets.

Market capitalization: 127.2 billion USD

Stryker sits at the intersection of hardware and software in healthcare, combining orthopedic implants and smart robotics like Mako with AI-assisted hospital and virtual care platforms. The company has debt on its balance sheet, and recent cyberattacks highlight how exposed connected hospital suppliers are. Revenue, return on equity forecasts, and continued investment in connected operating rooms, stroke care, and digital smart hospital services show that the business is still evolving. For investors interested in AI health tools backed by established and profitable medical device franchises, a key consideration is how the combination of growth, risk, and valuation fit together beyond the headlines.

Mako robotics and SmartHospital services hint at an AI engine that may be masking where the real value lies. See how analysts predict Stryker’s future and uncover pressure points that investors rarely discuss.

The three stocks mentioned here are just a starting sample. The Complete Transformative Artificial Intelligence (AI) Healthcare Stock Screener tells equally compelling stories of 34 more companies where AI is reshaping diagnostics, care delivery, and cost efficiency. Use Simply Wall St to identify, filter, and analyze the specific triggers and stories that matter to you so you can focus on the AI ​​healthcare ideas with the highest conviction.

Take control of your investment journey

If you think Stryker or any of these companies is a great opportunity, sign up for free on Simply Wall St and add top picks to your watchlist to keep an eye on stock prices relative to fair value for ideal entry points. Once migrated, manage your holdings with a portfolio command center that filters out the noise and delivers only the most important and actionable updates. Our community allows you to filter the best ideas from thousands of investor perspectives throughout your journey. Discover hidden catalysts and risks early to accelerate decision-making and stay ahead of the market.

Curious about alternative stock passes?

Fresh ideas can break out quickly from quiescence, and once momentum is established, optimal entry points can disappear. Please consider these lists carefully and consider whether any of them fit your approach.

This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.

Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email editorial-team@simplywallst.com.